University of California San Francisco
Give to UCSF<p>Pharmaceutical companies now have a guide — the UCSF-FDA TransPortal — to pre-clinical studies they should conduct to identify potentially harmful interactions between existing and new drugs that depend on how the drugs move into and out of cells through protein portals known as transporters.</p>
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.
A new approach to drug design, pioneered by a group of researchers at UCSF and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.
<p>A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal <em>Nature</em>.</p>